Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.27% and 1.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Q1 Earnings Lag Estimates

Shares of Quest Diagnostics (NYSE:DGX) rose 0.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 300.00% year over year to $3.76, which beat the estimate of $3.71.

Recap: Quest Diagnostics Q1 Earnings

SECAUCUS, N.J., April 22, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2021.

Quest Diagnostics Reports First Quarter 2021 Financial Results; Announces Plan for $1.5 Billion Accelerated Share Repurchase

Through the first quarter, Quest Diagnostics' (DGX) several significant strides in the field of COVID-19 diagnostic testing are expected to have contributed to the top line.

Molecular Tests to Drive Quest Diagnostics (DGX) Q1 Earnings

SECAUCUS, N.J. and HELSINKI, Finland, April 13, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Blueprint Genetics announced today that they will present results of 10 studies at the virtual 2021 American College of Medical Genetics and Genomics (ACMG) Annual Meeting, to be held  April 13–16, 2021.

Quest Diagnostics and Blueprint Genetics to Present New Insights from Genetic Testing at the 2021 Annual American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

American Express

Huntington Bancshares

Hanesbrands

Hologic

KeyCorp

PerkinElmer

Weyerhaeuser

Zions Bancorp

Bell-ringing S&P 500 profit reports are due out starting this week. And you should expect off-the-hook numbers from some companies.

Bell-Ringing Profit Is Coming From These 10 Companies

Celanese

Cincinnati Financial

State Street

Tyson Foods

As of April 9, the GuruFocus All-in-One Screener, a Premium feature, found that the following companies have low price-earnings ratios and high dividend yields.

5 Stocks Paying High Dividend Yields

SECAUCUS, N.J., April 7, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2021 financial results on Thursday, April 22, 2021, before the market opens.

Quest Diagnostics To Release First Quarter 2021 Financial Results On April 22

Quest Diagnostics (DGX) enters into an agreement with the CDC to provide genomic sequencing to identify new mutations in and patterns of transmission of SARS-CoV-2.

Quest Diagnostics (DGX) Rides on Test Sales Amid Volume Woe

Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.

Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions

Comcast

Cisco Systems

Dollar General

General Dynamics

Oracle

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They exhibit an average increase of 11.6% and a median increase of 8.7%.

7 Upcoming Dividend Increases To Start Q2

Quest Diagnostics Inc (NYSE: DGX) has announced selling the minority share in Q2 Solutions to IQVIA Holdings Inc (NYSE: IQV) for $760 million in cash. Q2 Solutions provides comprehensive testing, project management, supply chain, biorepository, biospecimen, and consent tracking solutions for clinical trials.

Quest Diagnostics Offloads Interest in Q2 Solutions JV To IQVIA

Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock

IQVIA Hlds

SECAUCUS, N.J. and RESEARCH TRIANGLE PARK, N.C.

Quest Diagnostics Sells Ownership Interest in Q² Solutions to IQVIA

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the acquisition of the 40 percent minority share of Q2 Solutions from Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, for $760 million, resulting in 100 percent ownership by IQVIA. The transaction has been fi

IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance

Quest Diagnostics has seen a strong cash windfall from COVID-19 testing, and recently expanded its buyback program. I see future growth potential from industry consolidation, and from expanded partnerships with hospitals for inpatient testing.

Quest Diagnostics: The Safest Dividend Is One That's Just Been Raised

Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.

Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care

SECAUCUS, N.J. and HELSINKI, March 15, 2021 /PRNewswire/ -- Zora Biosciences Oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods, today announced it has signed a non-exclusive license agreement with Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, for Zora's patented ceramide-analysis technology.

Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test

Quest Diagnostics Inc. said Thursday it will buy back $900 million of its own shares in the first half of 2021. In a statement released ahead of an investor day, the company said its long-term outlook is to achieve a compound annual growth rate of 4% to 5% for adjusted per-share earnings in the period from 2022 to 2024, and for the total company to grow 7% to 9%.

Quest Diagnostics to buy back $900 million of its own shares in first half

SECAUCUS, N.J., March 11, 2021 /PRNewswire/ -- At a virtual meeting with analysts and investors at its Investor Day, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will report on progress made on the company's two-point strategy to accelerate growth and drive operational excellence, and provide a new long-term financial outlook.

Quest Diagnostics Updates Strategic Growth Drivers and Provides Long-Term Outlook at 2021 Virtual Investor Day

SECAUCUS, N.J., and ST. LOUIS, March 8, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Mercy, one of the nation's most highly integrated, multi-state health care systems, today announced a definitive agreement for Quest to...

Quest Diagnostics and Mercy Broaden Access to Innovative, Convenient Lab Services in the Midwest

SECAUCUS, N.J., Feb. 24, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new COVID-19 testing service that aids in providing insight into an individual's immune response as a result of a recent or...

Quest Diagnostics Introduces New COVID-19 Semi-quantitative Serology Test Service

SECAUCUS, N.J., Feb. 23, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced changes in the leadership of its Board of Directors. Daniel C. Stanzione, Ph.D., 75, has decided to step down from his role...

Quest Diagnostics Announces Board Leadership Changes

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced an agreement with Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, to provide phlebotomy services to support Galleri™, GRAIL's multi-cancer early detection blood test. Quest Diagnostics maintains approximately 2,200 patient service centers and, through its ExamOne business, 5,000 mobile phlebotomists with exp

GRAIL and Quest Diagnostics Announce Collaboration to Support Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

NEW YORK and SECAUCUS, N.J., Feb. 16, 2021 /PRNewswire/ -- EmblemHealth, one of the nation's largest non-profit health insurers, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, have renewed their long-standing strategic relationship to...

News for Quest Diagnostics Stock (DGX)